

Ana Ruiz-Saenz graduated in Biochemistry and completed her Ph.D in Molecular Biology at the CBMSO in Madrid. For her postdoctoral studies, she joined the laboratory of Prof. Dr. Moasser at the University of California San Francisco (UCSF) where she worked on interdisciplinary projects focusing on the resilience of HER2-amplified cancers and the regulation of SRC kinases in cancer. Her work as a postdoc revealed new paradigms in cell signaling and cancer resistance that resulted in 12 manuscripts including first-authorships in Nature Cancer, Cancer Research and Oncogene. In 2019, she established her own research group as Assistant Professor at Erasmus MC in The Netherlands, supported by the Marie Skłodowska-Curie Actions Programme and the Dutch Research Council. And very recently, she joined CIC bioGUNE in Bilbao awarded with the Ikerbasque and Ramón y Cajal programmes.

Her aim is to uncover the impact of aberrant tumor glycosylation on the efficacy of targeted therapies integrating clinical data, co-culture 3D immune-cancer spheroids and high-content live-imaging. Specifically, her lab is currently deciphering the impact of altered glycosylation on the response to HER2-targeting agents in breast cancer, including a recent and promising therapeutic agent developed by AstraZeneca.

Her experience in the US and Europe has enabled her to establish fruitful collaborations with international experts and the pharmaceutical industry. She has also actively participated in numerous conferences and outreach activities, including fundraising events and science communication events.